

2,068 new cases were reported on the same day, taking the country's total confirmed cases to 115,678.

However, three more people died, raising Malaysia's Covid-19 death toll to 474.

followed by Kuala Lumpur (457) and Sabah (254).

According to him, prison and immigration depot clusters contributed 18 cases.

The three deaths recorded yesterday

among them is the JGWA Akasia cluster, where 117 confirmed positive Covid-19 cases were detected.

"This cluster involves the district of north east, southwest Seberang Perai Tengah and Seberang Perai

positive on Dec 26 via a targeted screening at the site.

"A total of 95 individuals were screened, with a total of 20 cases confirmed positive in the cluster," he said.

tested, where 18 positive cases were found in this cluster," he said.

Dr Noor Hisham also announced that 290 clusters had been declared as closed, after recording zero cases for 28 days straight.

THE STAR, SATURDAY 2 JANUARY 2021

Hong Seng Progressing towards an integrated healthcare group



HONG SENG
CONSOLIDATED BERHAD
(Formerly known as
MSCM Holdings Berhad)

HS Bio's Integrated Healthcare Supply Chain

Backed by Line Clear's logistic support



Legends:

Government and medical agencies Hospitals, medical centres & 6,000 private clinics nationwide End Consumers

Pantasniaga - Pantasniaga Sdn Bhd, a 51% subsidiary of HS Bio is in the business of provisioning of PCR test kits and test tubes set up for government and medical agencies.

eMedAsia - eMedAsia Sdn Bhd, a 52% subsidiary of HS Bio is a company that runs www.emedasia.com, an e-health digital platform by HCOOP MMA which aims to digitalise the private healthcare systems with access to potentially a network of 6,000 private clinics nationwide.

NeoGenix - NeoGenix Laboratoire Sdn Bhd, a 60% subsidiary of HS Bio is a medical diagnosis and research laboratory specialist providing various molecular infectious diseases diagnostics, genomics, Next Generation Sequencing (NGS) and other tests.

XABT MOU - Entered into a Memorandum of Understanding to potentially work together with Beijing Applied Biological Technologies Co., Ltd ("XABT") in the products and technology related to the Covid-19 including test kits, test machines and etc.

Yiling MOU - Entered into a Memorandum of Understanding to potentially work together with Shijiazhuang Yiling Pharmaceutical Co., Ltd ("Yiling") in the provision of their therapeutic and healthcare products.

Line Clear - HS Bio is working closely with Line Clear Express & Logistics Sdn Bhd, an express and logistics specialist with more than 68 hubs and depots nationwide and a fleet of 800 vehicles supported by IT-enabled system providing end-to-end supply chain management solutions including both road and air cargo logistics, warehousing, 3PL, 4PL and fulfilment.

In view of the challenges posed by the global pandemic, Hong Seng Consolidated Berhad ("Hong Seng") (Stock Code: 0041) or formerly known as MSCM Holdings Berhad through its healthcare supply chain specialist, HS Bio Supplies Sdn Bhd ("HS Bio") is working hard together with partners who are industry leaders in respective fields especially when it comes to fighting against Covid-19 in playing our part and helping the nation as we are all in this together.

HS Bio aims to be an end-to-end healthcare supply chain company with its main expertise in the ability to provide third party and fourth party logistics (3PL & 4PL) services for healthcare industries through our strategic partnership with Line Clear Express & Logistics Sdn Bhd ("Line Clear"). This means HS Bio will have a wide and penetrative reach in the market to distribute and disseminate pharmaceutical, medical and healthcare supplies such as e-medicine, medical consumables, bio supplies, medical equipment or devices, test-kits, vaccines, supplements, and other medical and healthcare related products as well as healthcare related services such as mobile testing facilities in addition to the supply chain management services for the healthcare industry.

Digitalising The Private Healthcare Sector Through eMedAsia




"eMedAsia provides an opportunity for the fragmented General Practitioners ("GP") to be united under a digital platform to sail through in the era of industrial revolution 4.0. It is a platform by Doctors for Doctors...~ in the best interest of our patients."

Dr. Thirunavukarasu Rajoo, Honorary General Secretary of Malaysia Medical Association, Chairman of Koperasi Persatuan Perubatan Malaysia (KOOP MMA) and Director of eMedAsia



Chris Chan, Director of eMedAsia.

Process Flow of eMedAsia's Business to Consumer (B2C) Model



HS Bio is an integrated healthcare provider (marketplace, payment, last mile delivery) -making healthcare more accessible and more affordable to more Malaysians.

"Through this collaboration, HS Bio have the ability to empower over 6,000 registered private clinics nationwide to leverage on technology to deliver end-to-end eHealthcare to millions of Malaysians by providing integrated solutions (3PL & 4PL, marketplace, payment, last mile delivery) to make healthcare more accessible and affordable to more Malaysians."

Currently, eMedAsia Sdn Bhd ("eMedAsia"), a 52% subsidiary of HS Bio and the company that runs the platform of www.emedasia.com which aims at digitalising the private healthcare sector via technology solutions has about 2,000 private clinic members in Malaysia. eMedAsia is jointly owned by Koperasi Persatuan Perubatan Malaysia ("KOOP MMA"), the investment vehicle for members of the Malaysian Medical Association (MMA), which is the main representative body for all registered medical practitioners in Malaysia. MMA has 14,000 registered doctors in its association, and 35,000 doctors on its

continuing professional development (CPD) platform.

In the case of Covid-19 tests, consumers or patients can easily have access to the clinics that are self-declared and trained to take swabs in conducting COVID 19 testing via the eMedAsia platform. They can book and get their digital certificates which are recognised by various authorities and the digital test certificates and results can also be easily integrated with the relevant authorities or travellers screening system for a seamless transmission of data. Essentially, the whole test screening process are stream-

lined through the platform facilitating no touch interactions and helps the doctors to conduct pre-assessment and digitalise the results and compliance with the various Ministry of Health's guidelines.

eMedAsia will also be able to leverage on multiple diagnostics and pathology laboratory partners such as NeoGenix Laboratoire Sdn Bhd, JSS Medical Lab Sdn Bhd and Geneflux Bioscience Sdn Bhd to offer consumers as well as its member clinics a wider range of lab services including Next Generation Sequencing ("NGS") technology.

Boosting HS Bio's Capabilities and Supply Chain with NeoGenix's Expertise



Dr. Kuan Chee Sian, Managing Director of NeoGenix who was recently awarded as one of the Ten Outstanding Young Malaysians 2020 in Medical Innovation by Junior Chamber International Malaysia (JCJ Malaysia)

In addition to eMedAsia's strong network of private clinics nationwide, HS Bio has also acquired a 60% stake in NeoGenix Laboratories Sdn Bhd ("NeoGenix"), a medical diagnostic and research and development ("R&D") laboratory specialist in molecular infectious diseases and oncological testing, utilising the techniques of standard PCR, real-time PCR, microarray, mass spectrometry and NGS technologies.

NeoGenix is the one of the earliest private MOH-approved laboratory to provide Covid-19 molecular testing and real-time RT-PCR to detect the presence of the SARS-CoV-2 virus and to diagnose active Covid-19 in assisting the country's effort to flatten the curve of infection.

In view of the crucial need of a medical diagnostic laboratory in screening the Covid-19 test samples collected nationwide, NeoGenix is planning to expand its capacity with additional two (2) labs in Klang Valley, two (2) labs including a mobile lab in Kota Kinabalu, Sabah and one (1) lab in Johor to accommodate and prepare for the increasing demand in screenings in line with the recent spike in cases.

“With the logistics support of our partner Line Clear, NeoGenix aspires to be the lab that offers the fastest turnaround time for the RT-PCR test screenings which is less than 48 hours while others may take between 48 to 72 hours. Line Clear’s staff have also been properly instructed and directed on how to handle the test samples to ensure zero breakage and failure in deliveries.”

NeoGenix's Short Term Expansion Plan For Its Covid-19 PCR Test Capacity



Hong Seng Aims To Support The Nation In Its Fight Against The Pandemic

As part of our support in the fight against the pandemic, HS Bio has sponsored two automatic real time test screening machines and PCR test kits to the authority of Sabah during the last outbreak when help was needed to ramp up testing.

Other than that, HS Bio through its subsidiary, Pantasniaga Sdn Bhd ("Pantasniaga"), a partner of BGI Genomics Co. Ltd which is a global leader in genomic sequencing services and proteomic services and the developer of the pioneer products and solutions used by the China Government during the beginning of the outbreak have also supplied PCR test kits to Malaysian government to curb the outbreak in Sabah.

With sourcing and distribution capabilities of Covid-19 and medical supplies coupled with the nationwide reach of eMedAsia's network of potentially up to 6,000 private clinics in Malaysia, HS Bio aims to lower down the cost of PCR test screenings for the public without compromising on quality and turnaround time as we are ready with the necessary preparation for a mass scale of affordable PCR test screenings ecosystem.

Not only that, the Group through its glove manufacturing arm, Hong Seng Gloves Sdn Bhd ("HS Gloves") has started commissioning six (6) units of Nitrile Butadiene Rubber ("NBR") double former glove dipping production lines with utilities support system for its plant located at Sungai Petani, Kedah.

The plant is expected to commence its first glove production by April 2021 and the company aims to expand to 16 production lines to produce up to 3.87

billion pieces of gloves per annum by August 2022.

In a recent announcement, the Group is also in the midst of acquiring a 105 acres land in Kedah Rubber City which is intended for its NBL plant. NBL is the main and crucial raw material used for the production of nitrile gloves which accounted for 70% of the total gloves exported from Malaysia according to Malaysian Rubber Glove Manufacturers Association ("MARGMA").

Due to the unprecedented demand and production of highly sought-after nitrile gloves caused by the pandemic, there is a shortage in NBL across the world leading to all-time high cost in securing NBL supply. Currently, there are many gloves players emerging in the market, however, not all of them have secured their NBL supply which may cause serious operational risks and unexpected material costs in the nitrile glove production as they may face a supply cut causing operation halts or procure its NBL supply at a premium cost thus affecting their margins.

Hence, by setting up its own NBL plant, it will provide a timely opportunity to secure constant internal supply for our subsidiary, HS Gloves's plant in Kedah and at the same time, filling the vacuum in the NBL shortage to capture the market.

Furthermore, Hong Seng also intends to

Gearing Up For A Post Covid-19 Future

As most of us are aware, Covid-19 won't be the last pandemic to hit us and there will be more and potentially more damaging pandemics that will occur in the near future. Thus, precision medicine which is an emerging approach for disease treatment and prevention that takes into account individual variability in genes, environment, and lifestyle for each person will be a key medical solution in tackling diseases that have thus far eluded effective treatments or cures. This approach will allow doctors and researchers to predict more accurately which treatment and prevention strategies for a particular disease will work in which groups of people.

Planning ahead, HS Bio through NeoGenix is setting up a R&D team to develop more testing assay with The College of American Pathologist's ("CAP") accreditation for early cancer or diseases detection tests such as human papillomavirus ("HPV"), also the culprit that causes human cervical cancer.

NeoGenix also offers various genomics services and NGS technologies as part of precision medicine for cancer treatment in which consumers may be able to get themselves tested at eMedAsia's member clinics for detection of viruses' genes.




Dato' Teoh Hai Hin, Executive Chairman of Hong Seng

“With the synergies of our current glove manufacturing business together with our upcoming nitrile butadiene latex (“NBL”) manufacturing business and integrated logistic services such as feedstock tank farm storage and delivery trucking, Hong Seng aims to be an integrated glove and NBL manufacturer in Malaysia by having both upstream and downstream segments of the glove manufacturing supply chain.”

venture into providing integrated logistics services such as feedstock tank farm storage and delivery trucking for NBL players through its wholly-owned subsidiary, HS Petchem Logistics Sdn Bhd which will enable the Group to be at the forefront of the glove production supply chain.


With all the above businesses and partnerships, Hong Seng is moulding itself to be an integrated healthcare group which has the capabilities and resources to uphold the nation's wellbeing.



丰成综合朝综合医疗集团迈进



HS Bio 综合医疗保健供应链



在面对全球大流行病的艰辛挑战中，丰成综合有限公司 (Hong Seng Consolidated Berhad; 股号: 0041; 前称为 MSCM 控股有限公司) 通过其医疗保健供应链专才 HS Bio Supplies 私人有限公司，致力与各领域的领先业者合作，在这场 2019 冠状病毒病的抗疫之战中助携手共进，帮助国家和国人一起度过难关。

HS Bio 放眼通过与 Line Clear Express & Logistics 私人有限公司的战略伙伴关系，发挥其专长为医疗保健领

域提供第三方和第四方物流 (3PL & 4PL) 服务，成为一家端到端的医疗保健供应链公司。这意味着 HS Bio 能更广、更深地渗入市场，以分销和推广药品、医学和医疗保健用品，例如电子医疗、医疗消耗品、生物用品、医疗设备或装置、测试器、疫苗和保健品、其他医学和医疗保健相关产品，以及医疗保健相关服务，比如说流动检测设施，辅助医疗保健领域的供应链管理服务。

通过 eMedAsia 数码化私人医疗保健领域



“eMedAsia 通过数码平台集合了散落各处的全科医生 (GP)，一起扬帆航向工业改革 4.0 的时代。这是一个医生为医生打造的平台……是为了患者最大的利益。”

马来西亚医药协会名誉秘书长、马来西亚医药协会合作社 (KOOP MMA) 主席、eMedAsia 董事 Thirunavukarasu Rajoo 医生


目前，由 HS Bio 持股 52% 的子公司、同时也是 www.emedasia.com 平台的运营公司 – eMedAsia 私人有限公司，在马来西亚拥有约 2000 家私人诊所会员，旨在通过科技解决方案来数码化私人医疗保健领域。eMedAsia 是由马来西亚医药协会合作社 (KOOP MMA) 联合持有，后者是为马来西亚医药协会 (MMA) 会员的投资工具，亦是马来西亚所有注册医生的主要代表组织。MMA 拥有 1 万 4000 名注册医生，在其持续专业发展 (CPD) 平台有 3 万 5000 位医生。

在冠病的逆转录酶聚合酶链反应检测方面，消费者或病患可以通过 eMedAsia 平台轻易地寻得已经自我申报、并经过培训以进行冠病拭子测试的诊所。他们可

以预定并取得由各种权威机构认证的数码证明书，这些数码证明书和测试结果可轻松地和相关权威机构或旅客检测系统结合，以实现无缝隙数据传输。整个测试检测过程通过该平台简化，而不需要交互触摸，并帮助医生进行预先评估和数码化结果，以及符合马来西亚卫生部的各项指南准则。

eMedAsia 也能够借助多家诊断和病理学实验室的合作伙伴，如 NeoGenix Laboratoire 私人有限公司、JSS Medical Lab 私人有限公司，以及 Geneflux Bioscience 私人有限公司，为消费者和诊所会员提供更广泛的实验室服务，包括下一代测序 (NGS) 技术。

eMedAsia 企业对消费者 (B2C) 模式流程



“通过这项合作，HS Bio 能够让逾 6000 家注册私人诊所借助科技的力量，通过公司所提供综合解决方案 (3PL & 4PL、网上市场、支付、最后一里路交付)，为数百万的马来西亚人提供端到端的电子医疗保健，这让更多马来西亚人更容易获得可负担价位的医疗保健服务。”

eMedAsia 董事 Chris Chan



在后疫情时代加速前进

相信大多数人都意识到，冠病不会是打击我们的最后一场大流行病，不久的将来可能还会有更具破坏性的大流行病。因此，精密医学将会是关键的医学解决方案，以应对迄今无法有效治疗或治愈的疾病。精密医学能考虑到每个人的基因、环境和生活方式来治疗和预防疾病。这种方法能够让医生和研究人员更准确地预测针对特定疾病的治疗和预防策略。

HS Bio 提前计划，通过 NeoGenix 成立了一支研发团队，和美国病理学家学院 (CAP) 开发更多测试和测定的方法，以用于检测早期癌症或疾病检测，例如人乳头瘤病毒 (HPV)，以及宫颈癌的罪魁祸首。

Neo Genix 还提供了各种基因组学服务和 NGS 技术，是治疗癌症的精密医学一部分，消费者能在 eMedAsia 的会员诊所进行病毒基因检测。

借 NeoGenix 专才强化 HS Bio 的供应链



NeoGenix 董事经理 Dr. Kuan Chee Sian，近期刚获马来西亚国际青年商会 (JCI Malaysia) 评为 2020 年马来西亚十大杰出医疗创新青年之一。


“有我们的合作伙伴 Line Clear 的物流支撑，NeoGenix 冀望成为 RT-PCR 检测周转时间最快的实验室，即少于 48 小时，而其他实验室可能需要 48 至 72 个小时。Line Clear 的员工已接受适当的训练和指导，以正确地处理测试样本，确保在运送过程中零破损并成功交付。”

除了 eMedAsia 在全国强劲的私人诊所网络，HS Bio 也收购了 NeoGenix Laboratoire 私人有限公司 60% 的股权，这是一家医学诊断与研发实验室，专长在分子传染病和肿瘤学检测，使用标准 PCR、实时 PCR、微阵列、质谱和 NGS 技术。

NeoGenix 是其中一家最早获得卫生部批准的私人实验室，以提供冠病分子检测和实时 RT-PCR，以检测 SARS-CoV-2 病毒和诊断正在活跃的冠病。在我国致力压平感染曲线的努力中助一臂之力。

由于全国迫切需要医学诊断实验室帮助检测冠病的测试样本，NeoGenix 计划扩大规模，在巴生谷增加 2 家实验室，在沙巴亚庇建设 2 家实验室 (包括流动实验室)，以及在柔佛增加 1 家实验室，以满足近期因病例激增而不断提高的检测需求。

NeoGenix 为 2019 冠状病毒病 PCR 测试工作的短期拓展计划



丰成冀望助国人一起抗疫



“随着我们当前的手套生产业务，以及接下来的丁腈乳胶 (NBL) 生产业务能产生协同效应，丰成的目标是成为涵括手套生产商供应链上下游的马来西亚综合手套和丁腈乳胶制造商。”

丰成执行主席 Dato' Teoh Hai Hin

在协助抗疫的过程中，我们在上一轮疫情爆发而急需检测时，HS Bio 为沙巴当局贡献了两台自动实时测试机器和 PCR 测试盒。

除此之外，HS Bio 通过其子公司 Pantasniaga 私人有限公司，为马来西亚政府提供 PCR 测试盒以抑制沙巴的疫情。Pantasniaga 是 BGI Genomics 有限公司的合作伙伴，后者是全球基因组测序服务和蛋白质组学服务的引领业者，所开发的创新产品和解决方案在疫情爆发初期获中国政府采用。

凭借着在冠病和医疗用品的采购和分销能力，加上 eMedAsia 的网络有潜力覆盖马来西亚全国高达 6000 家私人诊所，HS Bio 期望能在不影响质量和检测时间的前提下，为大众降低 PCR 检测的设备，因为本公司已经准备好创造大规模的可负担 PCR 检测生态系统。

不仅如此，本集团的手套制造臂膀——丰成手套私人有限公司，在位于吉打双溪大年的厂房，开始调试六条丁腈橡胶 (NBR) 双手手套生产线，并配备了公用事业支持系统。

该厂房预计会在 2021 年 4 月正式投产，放眼在 2022 年 8 月时扩展到 16 条生产线，以达到 38.7 亿只手套的年产量。

该集团近期也宣布正在收购吉打橡胶城

的 105 英亩土地，有意用于丁腈橡胶厂房。丁腈乳胶是生产丁腈手套的主要且关键原料，根据马来西亚橡胶手套生产协会 (MARGMA)，这类型手套占马来西亚总手套出口量的 70%。


由于大流行病引起空前需求，导致丁腈手套备受市场追捧，这导致全球丁腈乳胶短缺，需要用前所未见的高成本来确保丁腈乳胶供应重组。目前，越来越多手套业者在市场上崛起，却并非所有业者都获得足够的丁腈乳胶供应，恐将导致严重的营运风险或出乎意料的原料成本，因为他们在生产丁腈手套的过程中可能面临供应不足而导致停工，或需要以更高的价格来确保供应，进而影响了他们的利润。

而建立自己的丁腈橡胶厂房可说是非常适时的机会，能确保我们子公司丰成手套位于吉打的厂房有足够的供应，同时还能填补市场在丁腈乳胶的空缺。

再者，丰成还有意通过独资子公司 HS Petchem Logistics 私人有限公司提供综合物流服务，为丁腈橡胶业者储存原料储槽库和货运，让本集团在手套生产供应链中处于领先地位。

通过上述的所有业务和合作伙伴，丰成逐渐迈向成为一家综合医疗保健集团，拥有维护国家福祉的能力和资源。

丰成手套厂房产能和营业额预估




Hong Seng Progressing towards an integrated healthcare group





HS Bio's Integrated Healthcare Supply Chain

Backed by Line Clear's logistic support



Legends:



Pantasniaga – Pantasniaga Sdn Bhd, a 51% subsidiary of HS Bio is in the business of provisioning of PCR test kits and test labs set ups for government and medical agencies.

eMedAsia – eMedAsia Sdn Bhd, a 52% subsidiary of HS Bio is a company that runs www.emedasia.com, an e-health digital platform by KOOP MMA which aims to digitalise the private healthcare systems with access to potentially a network of 6,000 private clinics nationwide.

NeoGenix – NeoGenix Laboratoire Sdn Bhd, a 60% subsidiary of HS Bio is a medical diagnosis and research laboratory specialist providing various molecular infectious diseases diagnostics, genomics, Next Generation Sequencing (NGS) and other tests.

XABT MOU – Entered into a Memorandum of Understanding to potentially work together with Beijing Applied Biological Technologies Co., Ltd ("XABT") in the products and technology related to the Covid-19 including test kits, test machines and etc.

Yiling MOU – Entered into a Memorandum of Understanding to potentially work together with Shijiazhuang Yiling Pharmaceutical Co., Ltd ("Yiling") in the provision of their therapeutic and healthcare products.

Line Clear – HS Bio is working closely with Line Clear Express & Logistics Sdn Bhd, an express and logistics specialist with more than 68 hubs and depots nationwide and a fleet of 800 vehicles supported by IT-enabled system providing end-to-end supply chain management solutions including both road and air cargo logistics, warehousing, 3PL, 4PL and fulfilment.

In view of the challenges posed by the global pandemic, Hong Seng Consolidated Berhad ("Hong Seng") (Stock Code: 0041) or formerly known as MSCM Holdings Berhad through its healthcare supply chain specialist, HS Bio Supplies Sdn Bhd ("HS Bio") is working hard together with partners who are industry leaders in respective fields especially when it comes to fighting against Covid-19 in playing our part and helping the nation as we are all in this together.

HS Bio aims to be an end-to-end healthcare supply chain company with its main expertise in the ability to provide third party and fourth party logistics (3PL & 4PL) services for healthcare industries through our strategic partnership with Line Clear Express & Logistics Sdn Bhd ("Line Clear"). This means HS Bio will have a wide and penetrative reach in the market to distribute and disseminate pharmaceutical, medical and healthcare supplies such as e-medicine, medical consumables, bio supplies, medical equipment or devices, test-kits, vaccines, supplements, and other medical and healthcare related products as well as healthcare related services such as mobile testing facilities in addition to the supply chain management services for the healthcare industry.

Digitalising The Private Healthcare Sector Through eMedAsia




“eMedAsia provides an opportunity for the fragmented General Practitioners ("GP") to be united under a digital platform to sail through in the era of industrial revolution 4.0. It is a platform by Doctors for Doctors...~ in the best interest of our patients.”

Dr. Thirunavukarasu Rajoo, Honorary General Secretary of Malaysia Medical Association, Chairman of Koperasi Persatuan Perubatan Malaysia (KOOP MMA) and Director of eMedAsia



Chris Chan, Director of eMedAsia.

Process Flow of eMedAsia's Business to Consumer (B2C) Model



HS Bio is an integrated healthcare provider (marketplace, payment, last mile delivery) -making healthcare more accessible and more affordable to more Malaysians.

“Through this collaboration, HS Bio have the ability to empowers over 6,000 registered private clinics nationwide to leverage on technology to deliver end-to-end eHealthcare to millions of Malaysians by providing integrated solutions (3PL & 4PL, marketplace, payment, last mile delivery) to make healthcare more accessible and affordable to more Malaysians.”

Currently, eMedAsia Sdn Bhd ("eMedAsia"), a 52% subsidiary of HS Bio and the company that runs the platform of www.emedasia.com which aims at digitalising the private healthcare sector via technology solutions has about 2,000 private clinic members in Malaysia. eMedAsia is jointly owned by Koperasi Persatuan Perubatan Malaysia ("KOOP MMA"), the investment vehicle for members of the Malaysian Medical Association (MMA), which is the main representative body for all registered medical practitioners in Malaysia. MMA has 14,000 registered doctors in its association, and 35,000 doctors on its

continuing professional development (CPD) platform.

In the case of Covid-19 tests, consumers or patients can easily have access to the clinics that are self-declared and trained to take swabs in conducting COVID 19 testing via the eMedAsia platform. They can book and get their digital certificates which are recognised by various authorities and the digital test certificates and results can also be easily integrated with the relevant authorities or travellers screening system for a seamless transmission of data. Essentially, the whole test screening process are stream-

lined through the platform facilitating no touch interactions and helps the doctors to conduct pre-assessment and digitalise the results and compliance with the various Ministry of Health's guidelines.

eMedAsia will also be able to leverage on multiple diagnostics and pathology laboratory partners such as NeoGenix Laboratoire Sdn Bhd, JSS Medical Lab Sdn Bhd and Geneflux Bioscience Sdn Bhd to offer consumers as well as its member clinics a wider range of lab services including Next Generation Sequencing ("NGS") technology.

Boosting HS Bio's Capabilities and Supply Chain with NeoGenix's Expertise



Dr. Kuan Chee Sian, Managing Director of NeoGenix who was recently awarded as one of the Ten Outstanding Young Malaysians 2020 in Medical Innovation by Junior Chamber International Malaysia (JCI Malaysia)

“ With the logistics support of our partner Line Clear, NeoGenix aspires to be the lab that offers the fastest turnaround time for the RT-PCR test screenings which is less than 48 hours while others may take between 48 to 72 hours. Line Clear's staff have also been properly instructed and directed on how to handle the test samples to ensure zero breakage and failure in deliveries. ”

In addition to eMedAsia's strong network of private clinics nationwide, HS Bio has also acquired a 60% stake in NeoGenix Laboratoire Sdn Bhd ("NeoGenix"), a medical diagnostic and research and development ("R&D") laboratory specialist in molecular infectious diseases and oncological testing, utilising the techniques of standard PCR, real-time PCR, microarray, mass spectrometry and NGS technologies.

NeoGenix is the one of the earliest private MOH-approved laboratory to provide Covid-19 molecular testing and real-time RT-PCR to detect the presence of the SARS-CoV-2 virus and to diagnose active Covid-19 in assisting the country's effort to flatten the curve of infection.

In view of the crucial need of a medical diagnostic laboratory in screening the Covid-19 test samples collected nationwide, NeoGenix is planning to expand its capacity with additional two (2) labs in Klang Valley, two (2) labs including a mobile lab in Kota Kinabalu, Sabah and one (1) lab in Johor to accommodate and prepare for the increasing demand in screenings in line with the recent spike in cases.

NeoGenix's Short Term Expansion Plan For Its Covid-19 PCR Test Capacity



Gearing Up For A Post Covid-19 Future

As most of us are aware, Covid-19 won't be the last pandemic to hit us and there will be more and potentially more damaging pandemics that will occur in the near future. Thus, precision medicine which is an emerging approach for disease treatment and prevention that takes into account individual variability in genes, environment, and lifestyle for each person will be a key medical solution in tackling diseases that have thus far eluded effective treatments or cures. This approach will allow doctors and researchers to predict more accurately which treatment and prevention strategies for a particular disease will work in which groups of people.

Planning ahead, HS Bio through NeoGenix is setting up a R&D team to develop more testing assay with The College of American Pathologist's ("CAP") accreditation for early cancer or diseases detection tests such as human papillomavirus ("HPV"), also the culprit that causes human cervical cancer.

NeoGenix also offers various genomics services and NGS technologies as part of precision medicine for cancer treatment in which consumers may be able to get themselves tested at eMedAsia's member clinics for detection of viruses' genes.



Dato' Teoh Hai Hin, Executive Chairman of Hong Seng

“ With the synergies of our current glove manufacturing business together with our upcoming nitrile butadiene latex ("NBL") manufacturing business and integrated logistic services such as feedstock tank farm storage and delivery trucking, Hong Seng aims to be an integrated glove and NBL manufacturer in Malaysia by having both upstream and downstream segments of the glove manufacturing supply chain. ”

Hong Seng Aims To Support The Nation In Its Fight Against The Pandemic

As part of our support in the fight against the pandemic, HS Bio has sponsored two automatic real time test screening machines and PCR test kits to the authority of Sabah during the last outbreak when help was needed to ramp up testing.

Other than that, HS Bio through its subsidiary, Pantasniaga Sdn Bhd ("Pantasniaga"), a partner of BGI Genomics Co. Ltd which is a global leader in genomic sequencing services and proteomic services and the developer of the pioneer products and solutions used by the China Government during the beginning of the outbreak have also supplied PCR test kits to Malaysian government to curb the outbreak in Sabah.

With sourcing and distribution capabilities of Covid-19 and medical supplies coupled with the nationwide reach of eMedAsia's network of potentially up to 6,000 private clinics in Malaysia, HS Bio aims to lower down the cost of PCR test screenings for the public without compromising on quality and turnaround time as we are ready with the necessary preparation for a mass scale of affordable PCR test screenings ecosystem.

Not only that, the Group through its glove manufacturing arm, Hong Seng Gloves Sdn Bhd ("HS Gloves") has started commissioning six (6) units of Nitrile Butadiene Rubber ("NBR") double former glove dipping production lines with utilities support system for its plant located at Sungai Petani, Kedah.

The plant is expected to commence its first glove production by April 2021 and the company aims to expand to 16 production lines to produce up to 3.87

billion pieces of gloves per annum by August 2022.

In a recent announcement, the Group is also in the midst of acquiring a 105 acres land in Kedah Rubber City which is intended for its NBL plant. NBL is the main and crucial raw material used for the production of nitrile gloves which accounted for 70% of the total gloves exported from Malaysia according to Malaysian Rubber Glove Manufacturers Association ("MARGMA").

Due to the unprecedented demand and production of highly sought-after nitrile gloves caused by the pandemic, there is a shortage in NBL across the world leading to all-time high cost in securing NBL supply. Currently, there are many gloves players emerging in the market, however, not all of them have secured their NBL supply which may cause serious operational risks and unexpected material costs in the nitrile glove production as they may face a supply cut causing operation halts or procure its NBL supply at a premium cost thus affecting their margins.

Hence, by setting up its own NBL plant, it will provide a timely opportunity to secure constant internal supply for our subsidiary, HS Gloves's plant in Kedah and at the same time, filling the vacuum in the NBL shortage to capture the market.

Furthermore, Hong Seng also intends to

venture into providing integrated logistics services such as feedstock tank farm storage and delivery trucking for NBL players through its wholly-owned subsidiary, HS Petchem Logistics Sdn Bhd which will enable the Group to be at the forefront of the glove production supply chain.

With all the above businesses and partnerships, Hong Seng is moulding itself to be an integrated healthcare group which has the capabilities and resources to uphold the nation's wellbeing.

HS Gloves Manufacturing Plant Output Capacity & Revenue Forecasts

